Anavex Life Sciences Corp (AVXL)

[DoubleJ23]

Some deductive reasoning...

"To offer all participants access to ANAVEX®2-73 (blarcamesine) after completion of the ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett syndrome study[1] and the AVATAR Rett syndrome study[2], 12-week and 48-week open-label extension studies, respectively were initiated. Currently 90% and 100% of eligible participants have continued into the corresponding extension studies."

So for US trial we have 90% requesting extensions. That is either 9 out of 10 or 18 out of 20. No other possibilities. Since I know that 6 were enrolled in Part A, I'm going to guess they were able to recruit more than 4 patients in part B. So I'm going to conclude 20 patients have enrolled. So someone help me with my math...

total expected Rett patients in US = 21. If 20 patients have been enrolled, how many are left before this reaches full enrollment?